Effect of american cranberry (Cysticlean) on Escherichia coli adherence to bladder epithelial cells. In vitro and in vivo study.

OBJECTIVES: The American cranberry proanthocyanidins (PACs) are the main responsible for its efficacy in urinary tract infections. Their mechanism of action is related to inhibition of Escherichia coli to urothelial cells. Cysticlean contains an extract of American cranberry which provides 118 mg of PACs per dose. The activity of Cysticlean tablets on Escherichia Coli adherence to bladder epithelial cells has been studied in vitro. Moreover, the activity of Cistyclean both in powder for oral suspension and tablets has been compared ex-vivo. METHODS: The rats received both Cysticlean preparations per orem, and urine from each animal was collected during the following 16 hours and preincubated with E. coli. Subsequently, bacteria were incubated with T24 cells. After 1 hour the number of bacteria adhered per cell was calculated. For the in vitro study, E. Coli preincubated at various concentrations of the products were incubated with T24 cells and the same process previously referred was carried out. RESULTS: Urine samples from rats taking Cysticlean powder for oral suspension and tablets (118 mg PACs/animal) showed an important inhibition of E. Coli adherence (83% and 52%respectively). The inferior dose of 59 mg PACs/animal also showed marked inhibition of E. Coli adherence (29% after Cysticlean tablets intake and 40% for powder). In vitro, Cysticlean showed inhibition of bacterial adherence in all tested concentrations: 5, 25 and 75 PACs mg/ml, diminishing the number og bacteria adhered to epithelial cells by 25%, 36% and 34% respectively. CONCLUSIONS: Cysticlean shows a significant inhibition of E. Coli adherence to urothelial cells. Cysticlean powder for suspensión preparation is more effective tha tablets. Cysticlean powder for suspensión is well tolerated, and compliance has been observed. Its use is very recommendable in pediatric urinary tract infection prophylaxis. Due to the variety of products with American cranberry extracts in the market, with different proanthocyanidins declared content, it would be interesting to compare their activity using established pharmacological methods.

Efecto del arandano americano (Cysticlean®) sobre la adherencia de Escherichia coli a células epiteliales de vejiga. Estudio in vitro y ex vivo / Effect of american cranberry (Cysticlean®) on escherichia coli adherence to bladder epithelial cells. In vitro and in vivo study

OBJETIVO: Las proantocianidinas (PACs) del arándano americano son las principales responsables de su eficacia en infecciones del tracto urinario. Su mecanismo de acción está relacionado con la inhibición de la adherencia de Escherichia coli a las células uroepiteliales. Cysticlean® contiene un extracto de arándano americano que proporciona 118 mg de PACs por comprimido o sobre. Se ha estudiado in vitro, la actividad de Cysticlean® comprimidos sobre la adherencia de Escherichia coli a células epiteliales de vejiga. Además, se ha comparado, ex vivo, la actividad de Cysticlean® sobres y comprimidos.MÉTODOS: Las ratas recibieron por vía oral los dos productos de Cysticlean®, y durante las 16 horas posteriores se recogió la orina de cada animal, que fue preincubada con E. coli. Posteriormente, las bacterias se incubaron con células T24. Después de una 1 hora, se calcula el número de bacterias adheridas por célula. Para el estudio in vitro, E. coli preincubadas con varias concentraciones de los diferentes productos, se incuban con células T24 y se sigue el proceso anterior.RESULTADOS: Las muestras de orina de ratas que habían ingerido Cysticlean® sobres y comprimidos (118 mg PACs/animal) muestran una importante inhibición de la adherencia de E.coli (83% y 52%, respectivamente). A la dosis inferior de 59 mg PACs/animal, también presenta una destacada inhibición (29% tras el consumo de Cysticlean® comprimidos y 40% tras el consumo de Cysticlean® sobres). In vitro, Cysticlean® ha mostrado inhibición de la adherencia bacteriana a todas las concentraciones ensayadas. A las concentraciones de 5, 25 y 75 mg de PACs/mL, disminuye un 25%, 36% y 34%, respectivamente, el número de bacterias adheridas a las células epiteliales(AU)

CONCLUSIONES: Cysticlean® muestra una importante inhibición de la adherencia de E. coli a las células uroepiteliales. Cysticlean® sobres es más efectivo que Cysticlean® comprimidos. Con el uso de Cysticlean® sobres, se ha observado buena tolerancia, fidelidad en el tratamiento y su uso es también muy recomendable en la profilaxis de infecciones urinarias en pediatría. Dada la heterogeneidad de productos a base de extractos de arándano americano en el mercado, y su diferente contenido declarado de proantocianidinas, resulta de interés la comparación de su actividad por métodos farmacológicos establecidos(AU)

OBJECTIVES: The American cranberry proanthocyanidins (PACs) are the main responsible for its efficacy in urinary tract infections. Their mechanism of action is related to inhibition of Escherichia coli to urothelial cells. Cysticlean ® contains an extract of American cranberry which provides 118 mg of PACs per dose. The activity of Cysticlean® tablets on Escherichia Coli adherence to bladder epithelial cells has been studied in vitro. Moreover, the activity of Cistyclean® both in powder for oral suspension and tablets has been compared ex-vivo.METHODS: The rats received both Cysticlean® preparations per orem, and urine from each animal was collected during the following 16 hours and pre-incubated with E. coli. Subsequently, bacteria were incubated with T24 cells. After 1 hour the number of bacteria adhered per cell was calculated. For the in vitro study, E. Coli pre-incubated at various concentrations of the products were incubated with T24 cells and the same process previously referred was carried out.RESULTS: Urine samples from rats taking Cysticlean® powder for oral suspension and tablets (118 mg PACs/animal) showed an important inhibition of E. Coli adherence (83% and 52% respectively). The inferior dose of 59 mg PACs/animal also showed marked inhibition of E. Coli adherence (29% after Cysticlean® tablets intake and 40% for powder). In vitro, Cysticlean® showed inhibition of bacterial adherence in all tested concentrations: 5, 25 and 75 PACs mg/ml, diminishing the number og bacteria adhered to epithelial cells by 25%, 36% and 34% respectively(AU)

CONCLUSIONS: Cysticlean® shows a significant inhibition of E. Coli adherence to urothelial cells. Cysticlean® powder for suspensión preparation is more effective tha tablets. Cysticlean® powder for suspensión is well tolerated, and compliance has been observed. Its use is very recommendable in pediatric urinary tract infection prophylaxis. Due to the variety of products with American cranberry extracts in the market, with different proanthocyanidins declared content, it would be interesting to compare their activity using established pharmacological methods(AU)